Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Dianne Whitfield Sells 7,397 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Dianne Whitfield sold 7,397 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total value of $592,499.70. Following the transaction, the insider owned 38,958 shares in the company, valued at $3,120,535.80. This represents a 15.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS stock traded down $0.29 during trading hours on Thursday, hitting $77.48. The stock had a trading volume of 446,436 shares, compared to its average volume of 632,110. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.29 and a quick ratio of 4.25. The firm has a market capitalization of $3.29 billion, a PE ratio of -38.36 and a beta of 0.74. The stock’s 50 day moving average is $74.77 and its 200 day moving average is $57.68. Tarsus Pharmaceuticals, Inc. has a twelve month low of $38.51 and a twelve month high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 22.17% and a negative return on equity of 26.29%. The company had revenue of $118.70 million for the quarter, compared to analyst estimates of $114.22 million. As a group, research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Deep Track Capital LP raised its position in Tarsus Pharmaceuticals by 71.4% in the 3rd quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock worth $178,290,000 after purchasing an additional 1,250,000 shares during the last quarter. Paradigm Biocapital Advisors LP raised its stake in Tarsus Pharmaceuticals by 3.1% during the 1st quarter. Paradigm Biocapital Advisors LP now owns 2,610,197 shares of the company’s stock worth $134,086,000 after buying an additional 78,301 shares during the period. Jennison Associates LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 5.5% during the 3rd quarter. Jennison Associates LLC now owns 2,604,580 shares of the company’s stock valued at $154,790,000 after purchasing an additional 136,582 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Tarsus Pharmaceuticals by 5.3% during the first quarter. Vanguard Group Inc. now owns 2,226,595 shares of the company’s stock worth $114,380,000 after acquiring an additional 111,433 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in shares of Tarsus Pharmaceuticals by 25.1% during the third quarter. Assenagon Asset Management S.A. now owns 1,247,954 shares of the company’s stock worth $74,166,000 after buying an additional 250,367 shares in the last quarter. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have issued reports on TARS. Mizuho started coverage on shares of Tarsus Pharmaceuticals in a research note on Thursday, November 20th. They issued an “outperform” rating and a $100.00 price objective on the stock. Wall Street Zen upgraded shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. HC Wainwright boosted their target price on Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the stock a “neutral” rating in a research report on Monday, October 20th. Guggenheim upped their price objective on Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Tarsus Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $79.86.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.